3RB.DE - Reckitt Benckiser Group plc

XETRA - XETRA Delayed Price. Currency in EUR
76.54
+0.02 (+0.03%)
As of 12:12PM CET. Market open.
Stock chart is not supported by your current browser
Previous Close76.52
Open77.13
Bid76.50 x 900
Ask76.63 x 5000
Day's Range76.43 - 77.22
52 Week Range71.72 - 93.72
Volume3,472
Avg. Volume10,943
Market Cap51.955B
Beta0.83
PE Ratio (TTM)22.45
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.06 (2.49%)
Ex-Dividend Date2016-08-18
1y Target EstN/A
  • Is Reckitt Benckiser Group plc (LSE:RB) Undervalued?
    Simply Wall St.last month

    Is Reckitt Benckiser Group plc (LSE:RB) Undervalued?

    Reckitt Benckiser Group plc (LSE:RB.) saw significant share price volatility over the past couple of months on the LSE, rising to the highs of £75.07 and falling to the lowsRead More...

  • Exclusive: Pfizer to launch consumer health sale in November - sources
    Reuters2 months ago

    Exclusive: Pfizer to launch consumer health sale in November - sources

    Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters. Several global companies, including GlaxoSmithKline and Reckitt Benckiser, have expressed interest in bidding for the unit, which had sales of about $3.4 billion in 2016. The prospective sale, which is being led by Centerview Partners, Guggenheim Securities and Morgan Stanley, was first mooted on Oct. 10, when Pfizer said it was considering strategic options for the unit.

  • Reuters2 months ago

    Exclusive: Pfizer to launch consumer health sale in November -sources

    Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters. Several global companies, including GlaxoSmithKline and Reckitt Benckiser, have expressed interest in bidding for the unit, which had sales of about $3.4 billion in 2016. The prospective sale, which is being led by Centerview Partners, Guggenheim Securities and Morgan Stanley, was first mooted on Oct. 10, when Pfizer said it was considering strategic options for the unit.

  • The Wall Street Journal2 months ago

    [$$] Reckitt Makeover Clears Way for Pfizer Bid

    The London-listed consumer group is doing what activist Nelson Peltz wants Procter & Gamble to do—but M&A may be an ulterior motive.

  • The Wall Street Journal2 months ago

    [$$] Maker of Lysol, Durex Splits Business in Bid to Boost Growth

    The U.K.’s Reckitt Benckiser said it would divide operations into two parts, consumer health and home/hygiene, as it and other consumer-goods giants scramble to jump-start sales.

  • Reuters2 months ago

    FTSE rises to record close, blue-chips shrug off Reckitt blip

    British mid-caps jumped to a record closing level on Wednesday as investors grew more comfortable with the smaller, more domestically-focused stocks, while the FTSE 100 held its ground as third quarter earnings trickled in. The FTSE 250 (.FTMC) was up 0.6 percent on the day, closing at a record 20,263.1 points. Mid-caps have strongly outperformed the bigger index this year, up around 12 percent against the FTSE 100's 6 percent rise.

  • Reckitt to reshape as sales growth evaporates
    Reuters2 months ago

    Reckitt to reshape as sales growth evaporates

    Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.

  • Reuters2 months ago

    Reckitt to reshape as sales growth evaporates

    Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. The change follows ...

  • Pfizer's Advil May Be Just the Thing for Sickly Reckitt
    Bloomberg2 months ago

    Pfizer's Advil May Be Just the Thing for Sickly Reckitt

    The problem is getting shareholders to back a cash call to pay for it.

  • TheStreet.com2 months ago

    Reckitt Benckiser Misses Q3 Estimates, Cautions on Challenges Ahead

    Reckitt plans major restructuring after "soft" third quarter hits sales at consumer brands group

  • Reuters2 months ago

    Reckitt Benckiser to form two business units for better focus

    Reckitt Benckiser (RB.L) plans to reorganise its business into two distinct units, one for health and the other for hygiene and home products, as it tries to improve its flagging performance. The maker of Durex condoms, Nurofen tablets and Dettol cleaners announced the restructuring on Wednesday, along with its third-quarter sales figures. The British company made the decision to restructure after its June acquisition of U.S. baby formula maker Mead Johnson, which will account for roughly half of the larger health unit's sales.

  • Reckitt CEO Focuses on Health, Looking Beyond Worst Year
    Bloomberg2 months ago

    Reckitt CEO Focuses on Health, Looking Beyond Worst Year

    Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....

  • Forbes2 months ago

    3 FTSE 100 Stocks To Buy And Hold For The Next Decade

    On the hunt for blue chips with exceptional earnings profiles? Then step this way and look at the three profits powerhouses I have identified from Britain's FTSE 100 index.

  • At £67.53, Is Reckitt Benckiser Group plc (LSE:RB) A Buy?
    Simply Wall St.2 months ago

    At £67.53, Is Reckitt Benckiser Group plc (LSE:RB) A Buy?

    Reckitt Benckiser Group plc (LSE:RB.) trades with a trailing P/E of 22.3x, which is lower than the industry average of 23.9x. While this makes RB. appear like a great stockRead More...

  • McCormick (MKC) Tops Q3 Earnings, View Up on Acquisitions
    Zacks2 months ago

    McCormick (MKC) Tops Q3 Earnings, View Up on Acquisitions

    McCormick (MKC) posted upbeat results in third-quarter fiscal 2017. The company has also raised its sales, operating income and earnings guidance and expects lower currency impact on earnings.

  • Bloomberg3 months ago

    Reckitt Needs Some Boardroom Elbow Grease

    The new chairman has to take a hard look at the company's strategy.

  • Reuters3 months ago

    Reckitt Benckiser chairman to retire in 2018

    Reckitt Benckiser Group Chairman Adrian Bellamy will retire at its annual general meeting after 14 years in the post, the British consumer goods maker said on Tuesday. Christopher Sinclair, who has served on the board since 2015, will take on the role of non-executive chairman at that time, the company said. Sinclair, who has worked at PepsiCo, is currently executive chairman of the board at toymaker Mattel Inc.